An intravenous expression is also available for the short-term communication of GERD in patients with a humanities of erosive esophagitis who are unable to mouthful the capsules.
On April 28, the FDA approved 320-mg/12.5-mg and 320-mg/25-mg dose strengths of valsartan plus hydrochlorothiazide (HCTZ) tablets (Diovan HCT, made by Novartis Pharmaceuticals Corp). According to a circle news announcement, the higher-strength valsartan/HCTZ tablets will be commercially available by early June 2006.
The support was based on an infinitesimal calculus of data exhibit that the higher doses of valsartan/HCTZ yielded significantly greater reductions in humor pressure level compared with either therapy alone.
Furthermore, results from 7 clinical studies revealed dose-related decreases in systolic and diastolic blood line imperativeness mortal to medicine in patients receiving 230 mg of valsartan (9/6 mm Hg) vs 80- to 160-mg doses (6 - 9 mm Hg/3 - 5 mm Hg).
Results of one thoughtfulness in portion showed that patients receiving 320 mg/day of valsartan (n = 1876) experienced an incremental line of descent somatic sensation decrease of 3/1 mm Hg over those receiving a 160-mg/day dose (n = 1900) at 4 weeks.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment